drug

atypical antipsychotics:oral vs. long-acting route

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by State University of New York - Downstate Medical Center
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
PREvent First Episode Relapse (PREFER)
NCT00220714Phase 4Unknown

KOLs & investigators

1
Peter Handest, MD, Ph.d.KOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
State University of New York - Downstate Medical Center
company
trial
PREvent First Episode Relapse (PREFER)
PHASE4
trial
indication
Schizophrenia
indication
Patient Compliance
indication
Schizophrenia
indication
Recurrence
indication
KOL
Peter Handest, MD, Ph.d.
KOL score 5
person